The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and delayed-onset post-traumatic stress disorder (PTSD), currently in Phase III development in the US and Europe. Following positive Phase II trial data confirming that midoafetamine resulted in a significant reduction in PTSD symptoms, the FDA granted it a Breakthrough Therapy Designation in 2017.
Further results proceed to prove MDMA’s effectiveness in treating PTSD. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
